B Schlegelberger
Overview
Explore the profile of B Schlegelberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
2198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rathinam C, Sauer M, Ghosh A, Rudolph C, Hegazy A, Schlegelberger B, et al.
Leukemia
. 2021 Apr;
35(7):2139.
PMID: 33875794
No abstract available.
2.
Rathinam C, Sauer M, Ghosh A, Rudolph C, Hegazy A, Schlegelberger B, et al.
Leukemia
. 2021 Jan;
35(3):933.
PMID: 33504943
No abstract available.
3.
Ripperger T, Schlegelberger B
Pathologe
. 2018 Nov;
39(Suppl 2):306-310.
PMID: 30397787
Tackling the topic of genetic predisposition to childhood cancer requires close co-operation between pathologists, pediatric oncologists, and human geneticists. It is not just about the precise diagnosis and the most...
4.
Scholz C, Golas M, Weber R, Hartmann C, Lehmann U, Sahm F, et al.
Clin Genet
. 2018 Mar;
94(1):185-186.
PMID: 29498415
Ataxia-oculomotor apraxia type 4 (AOA4) is a rare autosomal recessive neurologic disorder. The phenotype is characterized by ataxia, oculomotor apraxia, peripheral neuropathy and dystonia. AOA4 is caused by biallelic pathogenic...
5.
Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb H, et al.
Leukemia
. 2017 Aug;
31(11):2398-2406.
PMID: 28804124
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430)...
6.
Stalke A, Skawran B, Auber B, Illig T, Schlegelberger B, Junge N, et al.
Clin Genet
. 2017 Aug;
93(3):665-670.
PMID: 28776642
Next-generation sequencing (NGS) has opened up novel diagnostic opportunities for children with unidentified, but suspected inherited diseases. We describe our single-center experience with NGS diagnostics in standard clinical scenarios in...
7.
Gaidzik V, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, et al.
Leukemia
. 2017 Jun;
32(1):30-37.
PMID: 28643785
We investigated the prognostic impact of minimal residual disease (MRD) monitoring in acute myeloid leukemia patients harboring DNA methyltransferase 3A-R882H/-R882C mutations (DNMT3A). MRD was determined by real-time quantitative PCR (RQ-PCR)...
8.
Ratnaparkhe M, Hlevnjak M, Kolb T, Jauch A, Maass K, Devens F, et al.
Leukemia
. 2017 Feb;
31(10):2048-2056.
PMID: 28196983
Recent developments in sequencing technologies led to the discovery of a novel form of genomic instability, termed chromothripsis. This catastrophic genomic event, involved in tumorigenesis, is characterized by tens to...
9.
Thol F, Klesse S, Kohler L, Gabdoulline R, Kloos A, Liebich A, et al.
Leukemia
. 2016 Nov;
31(6):1286-1295.
PMID: 27881874
We studied acute myeloid leukemia (AML) patients with lympho-myeloid clonal hematopoiesis (LM-CH), defined by the presence of DNA methyltransferase 3A (DNMT3A) mutations in both the myeloid and lymphoid T-cell compartment....
10.
Gaidzik V, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, et al.
Leukemia
. 2016 Nov;
30(11):2282.
PMID: 27804971
No abstract available.